Lumida
/ANGO
⌘K
AngioDynamics Inc

AngioDynamics Inc

ANGO
$15.47USD-0.96%-0.15 today

MARKET CAP

639.4M

P/E (TTM)

FWD P/E

DAY RANGE

$15 – $16

52W RANGE

$9
$16

AI Summary

Stalk
StalkMedium

Stage 2 advancing structure and active Momentum Breakout pattern confirm a bullish medium/long-term bias; however, price is extended above the short-term EMA band and in extreme overbought territory, making immediate execution unfavorable. Optimal engagement is deferred into pullbacks toward rising EMA support and prior resistance zones.

  • MedTech segment grew 19% YoY, comprising 47% of total revenue
  • Projected gross margins of 54%–55% in fiscal 2027 support profitability
  • Over 350 catheter lawsuits pose material financial and operational risk
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$291.0M$316.2M$338.8M$303.9M$292.5M
YoY %+10.2%+8.7%+7.1%-10.3%-3.8%
P / Sales3.1x2.4x1.1x0.8x1.4x
EV / Sales3.3x2.7x1.4x1.0x1.5x
Gross Profit, Adj.$156.8M$165.7M$174.2M$154.7M$157.7M
YoY %+4.3%+5.7%+5.1%-11.2%+1.9%
Margin %53.9%52.4%51.4%50.9%53.9%
EV / Gross Profit6.2x5.2x2.8x1.9x2.8x
EBITDA, Adj.$11.0M$9.9M$-5.8M$-5.2M$-14.2M
YoY %+12.1%-9.4%-158.1%+8.9%-169.8%
Margin %3.8%3.1%-1.7%-1.7%-4.8%
EV / EBITDA89.0x87.2x-83.9x-55.2x-30.9x
EBIT$-35.3M$-28.5M$-51.2M$-192.4M$-40.0M
YoY %+78.9%+19.3%-79.8%-276.0%+79.2%
Margin %-12.1%-9.0%-15.1%-63.3%-13.7%
EV / EBIT-27.6x-30.4x-9.4x-1.5x-11.0x
Net Income$-31.5M$-26.5M$-52.4M$-184.3M$-34.0M
YoY %+81.1%+15.9%-97.5%-251.5%+81.6%
Net Margin-10.8%-8.4%-15.5%-60.7%-11.6%
EPS (GAAP)-$0.82-$0.68-$1.33-$4.59-$0.83
YoY %+81.3%+17.1%-95.6%-245.1%+81.9%